Opioid hydromorphone (Dilaudid) does not help migraine

June 26, 2017

Unfortunately, opioid hydromorphone (Dilaudid) is still administered to 25% of patients with an acute migraine visiting an ER. Benjamin Friedman and his colleagues at the Montefiore Medical Center in the Bronx compared the efficacy of 1 mg of intravenous hydromorphone with an intravenous nausea medicine, prochlorperazine (Compazine), 10 mg plus diphenhydramine (Benadryl), 25 mg.

They presented their findings last month at the annual meeting of the American Headache Society. The study was blinded, but a safety monitoring committee stopped it early because the results were so lopsided. Prochlorperazine with diphenhydramine was twice as effective (60%) as hydromorphone (31%) in stopping a migraine and in preventing it from coming back within 48 hours.

So, if you end up in an ER for your migraine, refuse hydromorphone (Dilaudid), meperidine (Demerol), or any other opioid (narcotic) medication. Here is my old post with drugs other than prochlorperazine that are also effective.

Written by
Alexander Mauskop, MD
Continue reading
April 20, 2026
Can the Air You Breathe and the Weather Outside Trigger Your Migraines?
A major new study of over 7,000 migraine patients tracked two decades of air pollution, temperature, and humidity data, and found that the environment isn't just a background player. It's an active trigger.
Read article
April 17, 2026
Research
Not All Young Children Just “Bounce Back” from Concussion
A new study challenges the belief that young children quickly recover from concussions, showing that symptoms can persist for months and highlighting the importance of early evaluation and care.
Read article
April 10, 2026
Research
Migraines often strike on one side. Scientists say that matters more than we think
Migraines often strike on one side. Scientists say that matters more than we think New data may improve outcomes when we use TMS to treat migraines
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe